期刊文献+

脂肪干细胞复合PLGA对骨质疏松骨折愈合后生物力学的影响 被引量:10

Effect of Adipose Derived Stem Cells in PLGA on Biomechanics after Osteoporotic Fracture-healing
下载PDF
导出
摘要 目的探讨骨质疏松骨折后脂肪干细胞(ADSCs)复合聚乳酸共聚物(PLGA)对骨折愈合后生物力学的影响。方法建立大鼠骨质疏松骨折模型,将成功建立模型的27只大鼠分为治疗组(n=18)和空白对照组(n=9),治疗组大鼠的右侧股骨骨折肢为脂肪干细胞复合PLGA治疗组(ADSCs/PLGA组),左侧为单纯脂肪干细胞组(ADSCs组),于治疗后2、4、8周分别处死大鼠,取股骨测量新生骨痂的横截面积及相关生物力学指标。结果骨折后2周,与空白对照组和ADSCs组比较,ADSCs/PLGA组骨痂横截面积最大,空白组最小,各组间两两比较差异有统计学意义(P<0.05),骨折后4周各组间骨痂横截面积比较差异无统计学意义。各组剪切强度、弹性模量随着时间的推移,逐渐升高,各时间点均以ADSCs/PLGA组测定值最高,空白组最低,各组间比较差异均有统计学意义(P<0.01);剪切应变随着时间推移,逐渐降低,各时间点均是ADSCs/PLGA组测定值最低,空白组最高,各组间比较差异均有统计学意义(P<0.01)。最大载荷测定值在各时间点各组间比较为ADSCs/PLGA组最高,空白组最低,各组间比较差异均有统计学意义(P<0.01)。骨折后4、8周,最大应力测定值ADSCs/PLGA组最高,空白组最低,各组之间比较差异有统计学意义(P<0.01)。结论脂肪干细胞复合PLGA可以提高骨质疏松骨折后骨质愈合的质量,为临床骨质疏松骨折的治疗提供实验依据。 Objective To explore effect of adipose derived stem cells(ADSCs) in PLGA on biomechanics after osteoporotic fracture-healing.Methods 27 osteoporotic fracture model were randomized into control group(n=9) and experiment group(n=18).Starting from day 1,the sites of fracture were given different injections: triple distilled water for control group,ADSCs for the left femur of experimental group.ADSCs/PLGA were implanted in the right femur of experimental group through cutting the subcutaneous tissue.According to different times,the size of new callus were measured while biomechanics indexes were detected.Results Callus formation of the right femur was the most obvious after 2 weeks.This difference disappeared after 4 weeks.With the development of time,shear strength and modulus of elasticity gradually increased,shear strain gradually decreased,especially at the right femur.Compared the maximum load and stress,results showed statistical significance.Conclusion Local implation of ADSCs/PLGA may promote quality of osteoporotic fracture healing,which can provide new method for clinical practice.
出处 《宁夏医科大学学报》 2013年第3期244-247,共4页 Journal of Ningxia Medical University
基金 宁夏自然科学基金资助(NZ08132)
关键词 骨质疏松骨折 脂肪干细胞移植、PLGA 生物力学 osteoporotic fracture ADSCs/PLGA biomechanics
  • 相关文献

参考文献8

二级参考文献31

  • 1马兴,胡蕴玉,颜永年,熊卓,吕荣,王军,徐新智,白建萍.RP技术制备PDLLA/TCP人工骨载体与LD-PTH成骨效应相容性的体外实验[J].第四军医大学学报,2004,25(12):1081-1084. 被引量:2
  • 2李战强,黄友章,彭勤建,汪立川,解永学,廖丽.成人脂肪来源间充质干细胞的分离培养与鉴定[J].第四军医大学学报,2006,27(1):52-52. 被引量:9
  • 3薛延.骨质疏松症的流行病学概况[J].新医学,2007,38(1):7-8. 被引量:71
  • 4SITTINGER M, REITZEL D, DAUNER M, et al. Resorbable polyesters in cartilage engineering:, affinity and biocompatibility of polymer fiber structures to chondrocytes [J]. J Biomed Mater Res, 1996, 33(2): 57-63.
  • 5YOO HS, LEE EA, YOON JJ, et al. Hyaluronic acid modified biodegradable scaffolds for cartilage tissue engineering [J]. Bioma- terials, 2005, 26(14): 1925-1933.
  • 6WEI Y, HU H, WANG H, et al. Cartilage regeneration of adi- pose-derived stem cells in a hybrid scaffold from fibrin-modified PLGA[J]. Cell Transplant, 2009, 18(2): 159-170.
  • 7LEE JW, KIM YH, PARK KD, et al. Importance of integrin be- ta1-mediated cell adhesion on biodegradable polymers under serum depletion in mesenchymal stem cells and chondrocytes[J]. Biomaterials, 2004, 25(10): 1901-1909.
  • 8PARK GE, PATTISON MA, PARK K, et al. Accelerated chon- drocyte functions on NaOH-treated PLGA scaffolds[J]. Biomateri- als, 2005, 26(16): 3075-3082.
  • 9STOKES DG, LIU G, DHARMAVARAM R, et al. Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility- group box (SOX) transcription factors[J]. Biochem J, 2001, 360: 461-470.
  • 10MERCIER NR, COSTANTINO HR, TRACY MA, et al. Poly (lactide-co-glycolide) microspheres as a moldable scaffold for cartilage tissue engineering [J]. Biomaterials, 2005, 26: 1945-1952.

共引文献15

同被引文献115

  • 1刘雄.阿伦膦酸钠治疗原发性骨质疏松症的4年临床研究[J].现代生物医学进展,2009,9(24):4722-4724. 被引量:7
  • 2谢雁鸣,王和鸣,沈霖,高蕊,杜宝俊,林柄辉,田金洲,吴育宁.强骨胶囊治疗原发性骨质疏松症162例多中心随机对照临床研究[J].中医杂志,2004,45(7):506-509. 被引量:10
  • 3邱贵兴.骨质疏松性骨折——被忽视了的健康杀手[J].中华医学杂志,2005,85(11):730-731. 被引量:76
  • 4刘水冰,韩玲玲.钙尔奇D治疗骨质疏松症的临床观察[J].实用糖尿病杂志,2006,2(1):37-38. 被引量:4
  • 5Bianchi G, Czerwinski E, Kenwright A, et al. Long-term administration of quarterly Ⅳ ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the D1VA study long-term extension [J]. Osteoporosis international,2012,23(6): 1769-1778.
  • 6Sieber P, Lardelli P, Kraenzlin C A, et al. Intravenous bisphosphonates for postmenopausal osteoporosis: Safety profiles of zoledronic acid and ibandronate in clinical practice [J]. Clinical drug investigation, 2013,33(2):117-122.
  • 7Miller P D, Ragi Eis S, Mautalen C, et al. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease-the DIVINE study[J]. Bone,2011,49(6):1317-1322.
  • 8Vlak T, Kastelan D, Lozo P, et al. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia[J]. Clinical rheumatology,2011,30( 12): 1549-1554.
  • 9Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis - Analysis using a large scale, representative, longitudinal German database [J]. International journal of clinical pharmacology and therapeutics, 2012,50(5):315-322.
  • 10Rizzoli R. Bisphosphonates for post-menopausal osteoporosis:are they all the same?[J]. QJM, 2011,104(4):281-300.

引证文献10

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部